Custom-Network-Controls-Ltd near Lorette MB (1941 Result(s))

Since 1948, Barkman Concrete Ltd. has manufactured precast concrete products for residential, commercial, agricultural and municipal applications. We can also produce custom precast products for just about any need. We regularly ship our products throughout Canad,a US,a and Central America.A Commitment to ExcellenceAt barkman we are committed to product quality and customer satisfaction. All barkman products are guaranteed to meet or exceed the Canadian Standards Association (CSA) standards. We use only superior grade materials and employ stringent quality control measures throughout the manufacturing process to ensure a quality product every time. All barkman products are guaranteed against manufacturing defects.Lifetime WarrantyAll barkman residential products are warranted against manufacturing defects for as long as you own your home. Should your barkman product experience damage due to a manufacturing defect, barkman will cheerfully replace the damaged product free of charge (proof of purchase is required).

Our ProductsAGGRASTAT® - US GP IIb/IIIa inhibitor market - $400 million (AGGRASTAT® + two competitors)TARDOXALTM - in Phase II clinical development for the treatment of Tardive Dyskinesia - a large, unmet needAbout MedicureMedicure is a specialty pharmaceutical company engaged in the research, clinical development and commercialization of human therapeutics.HistoryMedicure founded in 1997 is a specialty pharmaceutical company engaged in the research, clinical development and commercialization of human therapeutics. Medicure has raised over $140 million and focused this investment on the advancement and clinical development of cardiovascular drugs. In 2006 Medicure acquired the USA commercial rights to AGGRASTAT (tirofiban HCl), a cardiovascular drug originally developed by Merck. AGGRASTAT, in combination with heparin, is indicated for the treatment of acute coronary syndrome. Medicurés business is generating revenue to support operations and to make selected investments in the clinical advancement of AGGRASTAT.TodayMedicurés core focus is on the US commercial sales of its FDA approved small molecule, AGGRASTAT.